BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 29560571)

  • 1. Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases.
    Chan DL; Dixon M; Law CHL; Koujanian S; Beyfuss KA; Singh S; Myrehaug S; Hallet J
    Ann Surg Oncol; 2018 Jun; 25(6):1768-1774. PubMed ID: 29560571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).
    Scott AT; Breheny PJ; Keck KJ; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
    Surgery; 2019 Jan; 165(1):166-175. PubMed ID: 30343949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms.
    Chakedis J; Beal EW; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha FG; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Marincola-Smith P; Cho C; Beems M; Pawlik TM; Maithel SK; Schmidt CR; Dillhoff M
    J Gastrointest Surg; 2019 Jan; 23(1):122-134. PubMed ID: 30334178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of cytoreductive operations for peritoneal carcinomatosis with or without liver cytoreduction in patients with small bowel neuroendocrine tumors.
    Wonn SM; Limbach KE; Pommier SJ; Ratzlaff AN; Leon EJ; McCully BH; Pommier RF
    Surgery; 2021 Jan; 169(1):168-174. PubMed ID: 32473829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?
    Maxwell JE; Sherman SK; O'Dorisio TM; Bellizzi AM; Howe JR
    Surgery; 2016 Jan; 159(1):320-33. PubMed ID: 26454679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery.
    Spolverato G; Bagante F; Aldrighetti L; Poultsides G; Bauer TW; Field RC; Marques HP; Weiss M; Maithel SK; Pawlik TM
    J Gastrointest Surg; 2017 Dec; 21(12):2039-2047. PubMed ID: 28744737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.
    Keck KJ; Choi A; Maxwell JE; Li G; O'Dorisio TM; Breheny P; Bellizzi AM; Howe JR
    Ann Surg Oncol; 2017 Aug; 24(8):2206-2212. PubMed ID: 28560597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making.
    Bertani E; Falconi M; Grana C; Botteri E; Chiappa A; Misitano P; Spada F; Ravizza D; Bazolli B; Fazio N
    Int J Surg; 2015 Aug; 20():58-64. PubMed ID: 26074290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery.
    Jaeck D; Oussoultzoglou E; Bachellier P; Lemarque P; Weber JC; Nakano H; Wolf P
    World J Surg; 2001 Jun; 25(6):689-92. PubMed ID: 11376398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis.
    Ejaz A; Reames BN; Maithel S; Poultsides GA; Bauer TW; Fields RC; Weiss M; Marques HP; Aldrighetti L; Pawlik TM
    J Surg Oncol; 2017 Dec; 116(7):841-847. PubMed ID: 28650564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Kostakis ID; Moris D; Schizas D; Cloyd JM; Pawlik TM
    J Gastrointest Surg; 2019 May; 23(5):1044-1054. PubMed ID: 30671800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center.
    Norlén O; Stålberg P; Öberg K; Eriksson J; Hedberg J; Hessman O; Janson ET; Hellman P; Åkerström G
    World J Surg; 2012 Jun; 36(6):1419-31. PubMed ID: 21984144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single Institution.
    Woltering EA; Voros BA; Beyer DT; Wang YZ; Thiagarajan R; Ryan P; Wright A; Ramirez RA; Ricks MJ; Boudreaux JP
    J Am Coll Surg; 2017 Apr; 224(4):434-447. PubMed ID: 28088602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?
    Xiang JX; Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    Ann Surg Oncol; 2018 Dec; 25(13):3928-3935. PubMed ID: 30218247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single institution's experience with surgical cytoreduction of stage IV, well-differentiated, small bowel neuroendocrine tumors.
    Boudreaux JP; Wang YZ; Diebold AE; Frey DJ; Anthony L; Uhlhorn AP; Ryan P; Woltering EA
    J Am Coll Surg; 2014 Apr; 218(4):837-44. PubMed ID: 24655881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.
    Galleberg RB; Knigge U; Tiensuu Janson E; Vestermark LW; Haugvik SP; Ladekarl M; Langer SW; Grønbæk H; Österlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
    Eur J Surg Oncol; 2017 Sep; 43(9):1682-1689. PubMed ID: 28522174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.
    Chambers AJ; Pasieka JL; Dixon E; Rorstad O
    Surgery; 2008 Oct; 144(4):645-51; discussion 651-3. PubMed ID: 18847650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors.
    Du S; Ni J; Weng L; Ma F; Li S; Wang W; Sang X; Lu X; Zhong S; Mao Y
    Medicine (Baltimore); 2015 Aug; 94(34):e1429. PubMed ID: 26313798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GEP-NETS update: a review on surgery of gastro-entero-pancreatic neuroendocrine tumors.
    Partelli S; Maurizi A; Tamburrino D; Baldoni A; Polenta V; Crippa S; Falconi M
    Eur J Endocrinol; 2014 Oct; 171(4):R153-62. PubMed ID: 24920289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.